{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,11,17]],"date-time":"2023-11-17T12:10:17Z","timestamp":1700223017345},"reference-count":38,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2004,4,12]],"date-time":"2004-04-12T00:00:00Z","timestamp":1081728000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pediatric Blood &amp; Cancer"],"published-print":{"date-parts":[[2004,7]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>These factors have been predictive for progressive disease on therapy (PDOT) among pediatric brain tumors: &gt;1.5 cm<jats:sup>2<\/jats:sup> unresectable tumor, glioblastoma, supratentorial primitive neuroectodermal tumor, and metastatic medulloblastoma (MBL). This pilot study sought to correlate cytoreductive response with progression free survival.<\/jats:p><\/jats:sec><jats:sec><jats:title>Procedures<\/jats:title><jats:p>Four courses of cisplatinum, cyclophosphamide, etoposide, and vincristine preceded hyperfractionated radiotherapy (RT). Maintenance chemotherapy consisted of eight cycles of carboplatin, etoposide, and vincristine. Biopsy specimens were immunohistochemically studied for labeling index, hypoxia, and multidrug resistance proteins.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Twenty newly diagnosed patients [nine primitive neuroectodermal tumors\/MBL, one choroid plexus carcinoma, eight malignant gliomas, and two anaplastic ependymomas] were treated. Ten patients, who required neuraxis irradiation, constituted the \u201cPNET\u201d group. These demonstrated five complete and one partial response (PR), with an estimated median progression free survival of 44 months and median survival in excess of 53 months. Patients treated with involved field irradiation were designated the \u201cGlioma\u201d group. Induction chemotherapy produced partial and minor responses (MRs) among 5\/10. Their estimated median progression free survival was 6.9 months (<jats:italic>P<\/jats:italic>\u2009=\u20090.035 relative to the PNET) with a median survival of 10.7 months (<jats:italic>P<\/jats:italic>\u2009=\u20090.04). Age, labeling index, the presence of hypoxia, and Pgp\/MDR1 expression failed to discriminate between the two groups.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>This induction regimen produced a cytoreductive response in 6\/10 and achieved a significant improvement in progression free survival among 7\/10 in the PNET group. Unfortunately, responses among Glioma patients did not translate into durable control. Expression of the biologic factors was similar between both groups and did not correlate with diagnosis or response. \u00a9 2004 Wiley\u2010Liss, Inc.<\/jats:p><\/jats:sec>","DOI":"10.1002\/pbc.20043","type":"journal-article","created":{"date-parts":[[2004,4,14]],"date-time":"2004-04-14T22:00:57Z","timestamp":1081980057000},"page":"46-54","source":"Crossref","is-referenced-by-count":10,"title":["Differential responsiveness among \u201chigh risk\u201d pediatric brain tumors in a pilot study of dose\u2010intensive induction chemotherapy"],"prefix":"10.1002","volume":"43","author":[{"given":"Mark T.","family":"Jennings","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anthony","family":"Cmelak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mahlon D.","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul L.","family":"Moots","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ray","family":"Pais","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu","family":"Shyr","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2004,4,12]]},"reference":[{"key":"e_1_2_7_2_2","first-page":"1307","article-title":"Tumor size, sensitivity to chemotherapy, and the design of treatment schedules","volume":"61","author":"Norton L","year":"1977","journal-title":"Cancer Treat Rep"},{"key":"e_1_2_7_3_2","doi-asserted-by":"publisher","DOI":"10.3171\/jns.1993.78.5.0767"},{"key":"e_1_2_7_4_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199306173282401"},{"key":"e_1_2_7_5_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1995.13.1.112"},{"key":"e_1_2_7_6_2","doi-asserted-by":"publisher","DOI":"10.1097\/00006123-199602000-00007"},{"key":"e_1_2_7_7_2","doi-asserted-by":"publisher","DOI":"10.1097\/00006123-199602000-00006"},{"key":"e_1_2_7_8_2","doi-asserted-by":"publisher","DOI":"10.3171\/jns.1998.89.1.0052"},{"key":"e_1_2_7_9_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1999.17.3.832"},{"key":"e_1_2_7_10_2","doi-asserted-by":"publisher","DOI":"10.1002\/ana.410120302"},{"key":"e_1_2_7_11_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1988.6.2.338"},{"key":"e_1_2_7_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/0360-3016(93)90203-8"},{"key":"e_1_2_7_13_2","doi-asserted-by":"publisher","DOI":"10.1097\/00043426-199803000-00007"},{"key":"e_1_2_7_14_2","first-page":"38","article-title":"Therapy of adult malignant brain tumors: What have the clinical trials taught us?","volume":"13","author":"Shapiro WR","year":"1986","journal-title":"Semin Oncol"},{"key":"e_1_2_7_15_2","doi-asserted-by":"publisher","DOI":"10.3171\/jns.1989.71.1.0001"},{"key":"e_1_2_7_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0360-3016(99)00369-7"},{"key":"e_1_2_7_17_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF02390176"},{"key":"e_1_2_7_18_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2002.04.109"},{"key":"e_1_2_7_19_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1995.13.7.1687"},{"key":"e_1_2_7_20_2","doi-asserted-by":"publisher","DOI":"10.1002\/1096-911X(20001201)35:6<719::AID-MPO52>3.0.CO;2-V"},{"key":"e_1_2_7_21_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1703213"},{"key":"e_1_2_7_22_2","doi-asserted-by":"publisher","DOI":"10.1016\/0022-510X(89)90007-5"},{"key":"e_1_2_7_23_2","doi-asserted-by":"publisher","DOI":"10.1093\/emboj\/17.11.3005"},{"key":"e_1_2_7_24_2","first-page":"1727","article-title":"A mathematical model for relating the drug sensitivity of tumors to their spontaneous mutation rate","volume":"63","author":"Goldie JH","year":"1979","journal-title":"Cancer Treatment Rep"},{"key":"e_1_2_7_25_2","doi-asserted-by":"publisher","DOI":"10.1097\/00043426-199711000-00002"},{"key":"e_1_2_7_26_2","doi-asserted-by":"publisher","DOI":"10.1002\/mc.2940070303"},{"key":"e_1_2_7_27_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF00172481"},{"key":"e_1_2_7_28_2","doi-asserted-by":"publisher","DOI":"10.1023\/A:1013845004294"},{"key":"e_1_2_7_29_2","doi-asserted-by":"publisher","DOI":"10.1097\/00006123-200206000-00011"},{"key":"e_1_2_7_30_2","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19920801)70:3<671::AID-CNCR2820700322>3.0.CO;2-P"},{"key":"e_1_2_7_31_2","doi-asserted-by":"publisher","DOI":"10.1080\/09553009414550131"},{"key":"e_1_2_7_32_2","first-page":"214","article-title":"Tumor hypoxia and the cell cycle: Implications for malignant progression and response to therapy","volume":"4","author":"Green SL","year":"1998","journal-title":"Cancer J"},{"key":"e_1_2_7_33_2","doi-asserted-by":"publisher","DOI":"10.1038\/379088a0"},{"key":"e_1_2_7_34_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF00182138"},{"key":"e_1_2_7_35_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF00170943"},{"key":"e_1_2_7_36_2","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.1997.408"},{"key":"e_1_2_7_37_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF01052726"},{"key":"e_1_2_7_38_2","doi-asserted-by":"publisher","DOI":"10.1097\/00001813-199911000-00001"},{"key":"e_1_2_7_39_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0147-0272(07)80004-3"}],"container-title":["Pediatric Blood &amp; Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fpbc.20043","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/pbc.20043","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,17]],"date-time":"2023-11-17T11:35:59Z","timestamp":1700220959000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/pbc.20043"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,4,12]]},"references-count":38,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2004,7]]}},"alternative-id":["10.1002\/pbc.20043"],"URL":"https:\/\/doi.org\/10.1002\/pbc.20043","archive":["Portico"],"relation":{},"ISSN":["1545-5009","1545-5017"],"issn-type":[{"value":"1545-5009","type":"print"},{"value":"1545-5017","type":"electronic"}],"subject":[],"published":{"date-parts":[[2004,4,12]]}}}